a study evaluating the efficacy and tolerability of veliparib in combination with paclitaxel/carboplatin-based chemoradiotherapy followed by veliparib and paclitaxel/carboplatin consolidation in adults with stage iii non-small cell lung cancer (nsclc)

Conditions: Non-small Cell Lung Cancer Stage III

Summary: this study seeks to establish * the recommended phase 2 dose (rptd) of veliparib in combination with concurrent paclitaxel/carboplatin-based chemoradiotherapy (crt) and consolidation with paclitaxel/carboplatin-based chemotherapy (phase 1 portion), and * to assess whether the addition of oral veliparib versus placebo to paclitaxel/carboplatin-based chemoradiotherapy with paclitaxel/carboplatin consolidation will improve progression-free survival (pfs) in adults with stage iii non-small cell lung cancer (phase 2 portion). a strategy decision was made not to proceed to phase 2 portion of this study due to change in standard of care.

this was to be a 2-phase study consisting of 1. a phase 1, dose escalation study of veliparib to determine a rptd for combination with concurrent paclitaxel/carboplatin-based crt and paclitaxel/carboplatin-based consolidation chemotherapy; followed by 2. a phase 2, randomized, double-blinded study to determine whether veliparib improved outcome relative to placebo when added to paclitaxel/carboplatin based crt followed by consolidation paclitaxel/carboplatin in adults with previously untreated stage iii nsclc. in the dose escalation phase (phase 1) of the study participants will be assigned to ascending doses of veliparib in combination with carboplatin, paclitaxel, and thoracic radiotherapy for 7 weeks following a traditional "3 + 3" design. the first cohort of at least 3 - 6 participants will receive veliparib 60 mg twice a day (bid) throughout crt. dose limiting toxicity (dlt) events will be collected for each dosing cohort until a new dosing cohort is opened or until the rptd is identified. participants will also receive a consolidation dose of veliparib of 120 mg bid + carboplatin and paclitaxel for up to two 21-day cycles. once the concurrent crt rptd is identified, an additional cohort will be enrolled to explore the tolerability of a consolidation dose of veliparib at 240 mg bid + carboplatin + paclitaxel for up to two 21-day cycles. following the dose escalation portion of the study, the rptd will be determined by the sponsor and the phase 2 portion of the study will begin with patient randomization in a 1:1:1 ratio to concurrent paclitaxel/carboplatin/radiotherapy/veliparib followed by consolidation paclitaxel/carboplatin/veliparib, concurrent paclitaxel/carboplatin/radiotherapy/veliparib followed by consolidation paclitaxel/carboplatin/placebo, or concurrent paclitaxel/carboplatin/radiotherapy/placebo followed by consolidation paclitaxel/carboplatin/placebo. randomization will be stratified by tumor volume (≤ 90 versus \> 90 cm³) and smoking history (current smoker versus former smoker versus never smoked). phase 2 was not carried out since during the study there was a change in standard of care for patients with newly diagnosed, unresectable stage iii nsclc.

Eligibility criteria:
inclusion criteria: 1. participants with histologically or cytologically confirmed stage iii non-small cell lung cancer (nsclc). 2. participants in the randomized portion of the study must have measurable disease per response evaluation criteria in solid tumors (recist), version 1.1 criteria. 3. participants must have v20 (volume of lung to receive 20 gy radiotherapy according to simulation) \< 35%. 4. participant must have an eastern cooperative oncology group (ecog) performance score of 0 - 1. 5. participant must have adequate hematologic, renal, hepatic, and lung function. 6. participant must consent to provide archived tissue or cytology sample of nsclc lesion for analysis. exclusion criteria: 1. participants with prior chemotherapy or radiotherapy (rt) for current nsclc. participants curatively treated for past early stage nsclc greater than 3 years ago may be included. 2. participants with prior exposure to poly-adenosine diphosphate (adp)-ribose polymerase (parp) inhibitors. 3. participants with known hypersensitivity to carboplatin, paclitaxel, or formulations containing polyethoxylated castor oil (cremophor). 4. participants with prior mediastinal or thoracic radiotherapy. prior tangential radiotherapy to prior breast cancer is acceptable. 5. participants with major surgery in the 4 weeks prior to randomization (video-assisted thoracoscopic surgery (vats) and/or mediastinoscopy is not considered major surgery). 6. participants with a previous or concurrent malignancy except for treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the patient received potentially curative treatment and has been disease-free for 3 years or is considered cured by the investigator if has been disease-free for less than 3 years. 7. participant is pregnant or lactating. 8. participant with sensory peripheral neuropathy of ≥ grade 2 at baseline, unable to swallow medication, or participants with prior history of seizure within the prior 12 months.

Keywords: veliparib parp inhibitor abt-888 first line previously untreated stage iii non-small cell lung cancer radiotherapy paclitaxel carboplatin